Breast Protocol - ADJUVANT - S1418

S1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab)as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Cancer or Positive Lymph Node.